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The mechanism of matrix metalloproteinase-8 (MMP-8) inhibition was investigated using ellipsomet-
ric measurements of the interaction of MMP-8 with a surface bound peptide inhibitor, tether-metal
abstraction peptide (MAP), bound to self-assembled monolayer films. MMP-8 is a collagenase whose
activity and dysregulation have been implicated in a number of disease states, including cancer metas-
tasis, diabetic neuropathy, and degradation of biomedical reconstructions, including dental restora-
tions. Regulation of activity of MMP-8 and other matrix metalloproteinases is thus a significant, but
challenging, therapeutic target. Strong inhibition of MMP-8 activity has recently been achieved via
the small metal binding peptide tether-MAP. Here, the authors elucidate the mechanism of this inhibi-
tion and demonstrate that it occurs through the direct interaction of the MAP Tag and the Zn2þ binding
site in the MMP-8 active site. This enhanced understanding of the mechanism of inhibition will allow
the design of more potent inhibitors as well as assays important for monitoring critical MMP levels in
disease states. VC 2016 American Vacuum Society. [http://dx.doi.org/10.1116/1.4948340]
I. INTRODUCTION
Matrix metalloproteinases (MMPs), including MMP-8, are
proteinases that degrade extracellular matrix (ECM) proteins
as well as other non-ECM proteins.1 They are crucial for nor-
mal biological function, but changes in the levels and activity
of MMPs have been associated with a variety of disease
states, including cancer metastasis, atherosclerosis, diabetes,
periodontal inflammation, pulmonary fibrosis, and tuber-
culosis.2–8 In addition, MMPs have been implicated in the
degradation of biomedical implants including dental restora-
tions.3,4,8–10 MMP-8 degrades collagen and has been shown
to be activated and to degrade the tooth structure around den-
tal restorations (specifically the type I collagen in dentin).8
Regulation of MMP-8 and other matrix metalloproteinases is
therefore a significant therapeutic target.4–7
Although the activity of MMP-8 is naturally regulated by
inhibitory proteins, dysregulation of MMP-8 has been found
in a variety of disease states, and thus, development of
specific small molecule and peptide-based inhibitors for
these MMPs has been an active area of research.11–15 MMP-
8 contains a large binding pocket with a flexible loop which
has hindered the development of very tight binding inhibi-
tors.15 It has recently been demonstrated that a small peptide
containing a metal binding sequence, tether-metal abstrac-
tion peptide (MAP), grafted to dental adhesive polymer for-
mulations, is a potent, effective inhibitor of MMP-8 activity,
but the mechanism of inhibition is not known.16 Several pos-
sibilities exist for the mechanism of action of this peptide-
based inhibitor including direct binding of the metal binding
MAP Tag within the Zn2þ binding pocket of MMP-8 [Fig.
1(a)] or abstraction of the zinc ion from MMP-8, resulting in
inactivation of the enzyme [Fig. 1(b)].
Understanding the mechanism of action is critical for future
developments of inhibitors and their implementation in bio-
medical reconstructions, devices, and therapies. In this work,
we demonstrate using ellipsometric studies at model self-
assembled monolayer (SAM) surfaces (Fig. 2) that there is a
direct interaction between the tether-MAP peptide and MMP-
8, which results in MMP-8 binding to the peptide-coated
a)Authors to whom correspondence should be addressed; electronic
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surface. Specifically, we have coupled the tether-MAP peptide
to amine-terminated SAM films via linking of the peptide
with the amine group on the surface through a disuccinimidyl
suberate (DSS) crosslinker [Fig. 2(a)]. Additionally, we uti-
lized control hydroxyl-terminated SAM surfaces, which do
not bind peptide, [Fig. 2(b)] for investigation of nonspecific
interactions of MMP-8 with the surface. The thickness of the
films is monitored at each step using ellipsometry. An increase
in thickness is observed when MMP-8 is deposited on the pep-
tide coated amine-terminated SAM but not on the control surfa-
ces. Furthermore, this interaction can be prevented by blocking
the metal binding site of the peptide with Ni2þ, which suggests
that the interaction specifically occurs through the metal bind-
ing MAP Tag at the Zn2þ binding pocket of the enzyme.
II. EXPERIMENT
A. Materials
Gold substrates (4 in. diameter 525 lm thick silicon wafers
with 100 nm of gold deposited with titanium adhesion layer)
were obtained from Platypus Technologies (Au.1000.SL1).
Thiols including 11-amino-1-undecanethiol, hydrochloride
(R-NH2) and 11-mercapto-1-undecanol (R-OH) were
obtained from Sigma-Aldrich. Dimethyl sulfoxide (DMSO),
triethylamine, sodium phosphate dibasic, sodium hydroxide
(NaOH), sodium dodecyl sulfate (SDS), Triton X-100
(Triton), and ethylenediaminetetraacetic acid (EDTA) were
obtained from Sigma-Aldrich. Two-hundred proof ethanol
was obtained from Decon laboratories. (4-(2-hydroxyethyl)-1-
piperazineethane sulfonic acid) (HEPES), sodium chloride,
potassium chloride, potassium phosphate monobasic, Tris
base, hydrochloric acid (HCl), chloroform, acetone, acetic
acid, nickel sulfate hexahydrate, and zinc sulfate were
obtained from Fisher Scientific. DSS, a homobifunctional
crosslinker, was obtained from ProteoChem. Milli-Q water
(resistivity >17 MX  cm) was used throughout.
Peptide SWLAYPGAVSYRGNCC (tether-MAP) was
custom synthesized by GenScript (>95% purity), provided
in small aliquots and stored at 20 C to reduce freeze/thaw
cycles of the peptide. Peptide was allowed to equilibrate to
room temperature prior to hydration and use.
1. MMP-8 protein production
The catalytic domain of MMP-8 was engineered into a
fusion construct and the protein expressed in Escherichia
coli as previously described.17 In the present study, two var-
iants of MMP-8 were used. Both contain an N-terminal
thioredoxin-S Tag fusion partner and a polyhistidine tag for
purification (MMP-8 fusion), and in addition, one contained
the metal-binding claMP Tag and a spacer sequence inserted
between the fusion partner and MMP-8 (claMP-link-MMP-8
fusion). Immobilized metal affinity chromatography was
used to purify the fusion protein from the soluble fraction of
the cell lysate. The thioredoxin and S Tag were cleaved by
thrombin and Factor Xa to release MMP-8 (which also
removed the polyhistidine purification tag). Catalytic activity
was determined using MMP-8 Fluorescent Drug Discovery
Kit, RED (Enzo Life Sciences) according to the manufac-
turer’s instructions. Complete inhibition of the fusion
enzyme was accomplished using N-Isobutyl-N-(4-methoxy-
phenylsulfonyl)glycyl hydroxamic acid (NNGH).
2. Buffers
HEPES buffer pH 7.4 (20 mM HEPES, 200 mM potas-
sium chloride, pH adjusted to 7.4 with 1 M NaOH), potas-
sium phosphate buffer pH 7.4 (137 mM NaCl, 2.7 mM KCl,
10 mM Na2HPO4, and 1.8 mM KH2PO4, pH adjusted to 7.4
with 1 M NaOH), Tris buffer (20–200 mM Tris base, pH
adjusted to 7.4 with 1 M HCl), protein buffer (50 mM Tris-
Cl, 60 mM NaCl buffer, pH 7.9), Enzo Life Sciences MMP-
8 Fluorometric Drug Discovery Kit, RED assay buffer
(50 mM HEPES, 10 mM CaCl2, 0.05% Brij-35, pH 7.5), and
acetate buffers (50 mM acetate buffer pH 3.5, 50 mM acetate
buffer pH 3.5 with 10 mM EDTA, 50 mM acetate buffer pH
4.5 with 10 mM EDTA) were all utilized.
B. Methods
1. Ellipsometry
Film thicknesses were determined under ambient condi-
tions using a single wavelength Rudolf Auto EL III ellip-
someter at a wavelength of 632.8 nm with an incident angle
of 70. For each sample, averaged optical constants deter-
mined from measurements at 5–7 different spots for each
gold piece were determined on each freshly cleaned gold
sample. The optical constants showed some variability
among different gold samples but typical values were
n¼ 1.5 and k¼ 3.5. A refractive index of n¼ 1.465 was
assumed for the organic, peptide, and protein layers for all
FIG. 1. Potential mechanisms of MMP-8 inhibition by tether-MAP peptide.
(a) Shared Zn2þ binding between MMP-8 and tether-MAP, or
(b) Abstraction of Zn2þ from MMP-8 by tether-MAP.
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samples.18–20 Additionally, a negligible absorptivity of the
films (k¼ 0) at the wavelength of the measurement
(632.8 nm) was assumed. This has been verified with UV-
Vis measurements of the peptide and protein (unpublished
data). Approximately five to seven measurements at different
spots on the surface were obtained for each sample with a
minimum of three different samples for each surface termi-
nation (amine and hydroxyl).
2. Contact angle goniometry
Static water contact angles were determined via goniome-
try using a Rame Hart goniometer by adding deionized water
to the surface to form a drop and measuring the contact angle
between the surface and water from both sides of this water
droplet. This was performed in triplicate with water droplets
randomly distributed on each surface.
3. SAM film formation
Gold substrate samples of approximately 1–3 cm2 were cut
from gold wafers using a diamond-tipped scribe. These sam-
ples were rinsed with deionized water and dried with nitrogen
gas. Gold substrates were rinsed with chloroform, acetone,
and ethanol and then dried with nitrogen gas. Optical con-
stants for each gold substrate were obtained via ellipsometry.
Gold substrates were then rinsed with solvents again. SAMs
were prepared by immersing these cleaned gold substrates
into respective thiol solutions for a minimum of 24 h. At least
three replicate samples were prepared for each experiment.
Hydroxyl-terminated thiol (11-mercapto-1-undecanol, HS-
(CH2)11-OH or R-OH) solutions (2 mM) with ethanol as the
solvent were prepared as control samples. Amine-terminated
thiol (11-amino-1-undecanethiol, hydrochloride, HS-(CH2)11-
NH2HCl or R-NH2) solutions of 0.5 mM in ethanol spiked
with 3% triethylamine were prepared (conditions to minimize
bilayer formation).21 After incubation, R-OH samples were
removed from solution, rinsed with ethanol and water, and
dried with nitrogen gas. Samples incubated in R-NH2 thiol
were removed from solution, rinsed with ethanol, acetic acid
(to disrupt any potential bilayer formation), and ethanol again,
and dried with nitrogen gas. Thicknesses of monolayer sam-
ples were measured via ellipsometry and contact angles were
measured via goniometry to verify functionalization of the
gold surfaces.21–27 See Table I for values of typical initial
thicknesses and contact angles for each type of monolayer
sample. The slightly larger thickness of the R-NH2 sample
relative to the R-OH samples is likely the result of either par-
tial bilayer formation on the amine sample or differences in
packing between the two samples. This difference is reprodu-
cibly observed from sample to sample and consistent with
previous literature. In addition, AFM measurements on simi-
lar samples indicate RMS roughness values comparable to the
bare gold substrates used (1 nm) on both types of samples.
4. Mixed SAMs formation
Mixed SAMs were prepared in mixtures of 10:90
(0.2:2 mM), 25:75 (0.5:2 mM), and 50:50 (0.5:0.5 mM) of R-
NH2:R-OH to make SAMs approximately 10%, 25%, and
50% amine-terminated, respectively. All mixed thiol solu-
tions contained the 3% triethylamine spike. Gold surfaces
and SAMs were prepared and characterized as above for the
100% SAMs (Table I).
5. Coupling of peptide to surfaces
DSS was used to covalently couple the N-terminal amine
of the peptide (tether-MAP) to the amine-terminated surface
groups. To perform this step, directions from ProteoChem’s
Product Information Sheet and General Protocol were fol-
lowed with slight modifications. A stock solution of 1–2 mg/
FIG. 2. Schematic of binding studies on (a) amine-terminated SAM and (b) hydroxyl-terminated (control) SAM films. For each scheme: Step (1) initial SAM
film, (2) after tether-MAP coupling, and (3) after MMP-8 incubation.
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ml (or 0.57–1.1 mM) tether-MAP was prepared in potassium
phosphate buffer pH 7.4. Ninety-four microliters of 20 mM
HEPES buffer pH 7.4 was added to each sample surface. This
was followed by sequential addition and mixing of 4 ll of
0.57–1.1 mM tether-MAP in buffer and typically 2 ll
50–75 mM DSS in DMSO. Samples were incubated in a cov-
ered container protected from light for approximately 60–75
min (increased from manufacturer’s recommendation to allow
time for diffusion and reaction at the surface). Variability in
the DSS activity was observed from lot to lot, and thus, opti-
mization of the DSS concentration for each batch was
required.
The reaction was quenched with 50–100 ll of 20–200 mM
Tris buffer (for approximately 15 min). Samples were then
rinsed with HEPES buffer and water and dried with nitrogen
gas. To remove nonspecifically bound peptide and/or cross-
linker, samples were incubated in a mixture of 0.5% SDS
with 0.5% Triton for approximately 20–60 min. Samples
were rinsed three times with 0.5% SDS and then with buffer
and deionized water before being dried with nitrogen gas and
characterized using ellipsometry.
6. MMP-8 and tether-MAP interaction
To observe potential interaction of MMP-8 with the tether-
MAP, MMP-8 was diluted in protein buffer to make secondary
stock solutions and then further diluted five-fold to a range of
concentrations between 0.01 and 10 lM in Enzo kit assay
buffer. This diluted protein of 50–100 ll was placed on each
sample surface for 100–110 min. After incubation, samples
were rinsed with HEPES buffer and water and dried with nitro-
gen gas. Ellipsometry was utilized to characterize the samples.
7. Removal of surface bound MMP-8
Attempts were made to remove MMP-8 bound to the sur-
face by soaking samples in denaturing solution (either 0.5%
SDS or 0.5% SDS/0.5% Triton) for 30–60 min. Metal bind-
ing to MAP requires neutral to basic pH.28 Therefore, sam-
ples were subsequently rinsed with acetate buffers pH 3.5,
pH 3.5 with EDTA, and pH 4.5 with EDTA, and then incu-
bated in acetate buffer pH 4.5 with EDTA for several hours
to disrupt MAP binding to Zn2þ.
III. RESULTS AND DISCUSSION
Inhibition of MMP-8 by the tether-MAP peptide has been
demonstrated previously, but the mechanism for this
inhibition had not yet been investigated. Based on knowledge
of the MAP chemistry, two likely possibilities exist for the
mechanism of MMP-8 inhibition including: (1) shared bind-
ing of the zinc ion in MMP-8’s active site by the MAP
sequence or (2) removal by abstraction of the zinc ion from
the catalytic portion of the MMP-8 by the MAP Tag (Fig. 1).
This ellipsometric study was designed to test the mechanism
for MMP-8 inhibition by tether-MAP. Should the substan-
tially larger 18-kDa MMP-8 protein bind to the peptide on the
tether-MAP-modified SAM surface, a significant increase in
height would be expected after the protein incubation step. If
the peptide abstracts zinc ions from the MMP-8, a very mini-
mal change in height would be expected because the protein
would diffuse away from the surface rather than remain
bound and the small size zinc ion remaining would not result
in a measurable thickness change (Fig. 6). We used model
SAM surfaces and ellipsometry to investigate this inhibition
mechanism by determining the thickness of the surface bound
film at each stage in the experiment.
A. Protein preparation
Sufficient quantities of active, pure MMP-8 are not avail-
able commercially at an affordable price for such mechanistic
investigations. Our group has recently developed methods of
preparing a relatively stable, active, inhibitable MMP-8 fusion
construct.17 Two different protein variants were used in the
investigations described here: claMP-link-MMP-8 fusion and
MMP-8 fusion.17 Each of these proteins has been character-
ized extensively and shown to be catalytically active and
inhibited by the standard inhibitor NNGH, both in the fusion
construct and following cleavage to release the tags. Once the
fusion partner in each of these constructs is cleaved to release
the MMP-8 domain, significant fragmentation of the enzyme
is observed over time along with a decrease in activity. While
the cleaved MMP-8 constructs degrade with time, they retain
catalytic activity for time periods long enough for experi-
ments such as those described here. Separation of residual
intact fusion protein is easily achieved, but in the cleaved
samples used in these studies, a mixture of MMP-8 cleavage
fragments remains. For these reasons, two different catalyti-
cally active protein variants with different cleavage fragments
were used to verify that the results obtained in this study are
not due to the fusion partner or residual contamination with
other fragments. Because of the significant degradation prod-
ucts and cleavage fragments, the protein concentrations
reported here reflect total protein content in the sample, not
the concentration of intact MMP-8, which may vary from
batch to batch. Stability analysis confirms that the activity is
retained with cold storage for several days. Experiments were
run within 4 days after cleavage, and protein was typically
stored refrigerated until samples were used to minimize the
amount of degradation. Based on the characterization of activ-
ity and stability presented in McNiff et al.,17 sufficient quanti-
ties of active MMP-8 are present in these samples to
investigate the mechanism of interaction between MMP-8
and tether-MAP.
TABLE I. Typical thicknesses and contact angles for SAM films.
SAM (R-NH2:R-OH) Thickness (Å) Contact angle (deg)
R-OH 11.9 6 0.8 21 6 1
10:90 12.9 6 0.6 22 6 4
25:75 13.8 6 0.8 23 6 2
50:50 17.4 6 0.7 32 6 1
R-NH2 18.8 6 1.1 45 6 3
a
aContact angles as low as 25 have been observed on some samples.
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B. Surface coupling of peptide inhibitor
Experiments were carried out in parallel on hydroxyl- and
amine-terminated SAMs (or mixtures thereof), as shown in
Fig. 2. Briefly, SAMs were characterized, exposed to the
crosslinking solution for tether-MAP attachment, rinsed,
dried, and characterized. Additionally, mixed SAMs were
used to determine if packing density might impact the
peptide–protein interaction.
SAMs were initially characterized via ellipsometry and
goniometry to confirm the formation of the monolayers and
determine the packing adequacy as well as wettability.
Initial values (Table I) were similar to literature values.21–27
Next, peptide was grafted to the surface of the SAM using a
homobifunctional crosslinker, DSS, which consists of a
linker with an amine-reactive N-hydroxysuccinimide ester
group at each end. These esters will form amide bonds with
primary amine groups, releasing the N-hydroxysuccinimide
groups in the process. The N-terminal amine of the tether-
MAP peptide was grafted to the amine-terminal group on the
amine containing surfaces via this crosslinker (while no
reaction was expected on the hydroxyl-terminated surfaces).
Figure 3 shows that when the tether-MAP peptide is coupled
to the amine-terminated SAM film, a large increase in thick-
ness is observed, but no increase is observed in the case of
the hydroxyl-terminated films. On the amine-terminated
SAM, this orients the peptide such that the MAP Tag is
exposed at the surface and available for further reaction.
After covalently attaching the tether-MAP to the amine-
terminated surface [Fig. 2(a)], an increase in height of less
than or equal to 25 Å for the coupling step was expected
(11.4 Å for the homobifunctional crosslinker and 14 Å for
the peptide based on the product data sheet and simple
Chem3D models of the molecules), presuming a uniform
packing of upright, optimized geometry peptide and cross-
linker to the surface. Our values of 16–22 Å were consistent
with this expectation. The slightly lower than maximum the-
oretical thickness is likely due to steric hindrance of the rela-
tively bulky peptide on the surface inhibiting reaction with
neighboring sites and charge repulsion between neighboring
peptide molecules.
C. claMP-link-MMP-8 fusion construct binding to
peptide inhibitor
Once the peptide was coupled to the surface, the samples
were incubated in protein solution, washed, and dried. The
measured thicknesses for one concentration of claMP-link-
MMP-8 fusion construct on both the control and the amine-
terminated SAMs are shown in Fig. 3.
For the control R-OH SAMs, no significant change in
height throughout the course of these experiments was
observed, which was expected because no crosslinking of
the peptide should occur with surface hydroxyl groups and
only nonspecific interactions between MMP-8 and the R-OH
surfaces are possible. In the case of the R-NH2 SAM, an
increase in thickness was observed after the peptide coupling
step as well as after MMP-8 incubation. This indicates that
(1) the peptide is coupled to the amine surface and (2) the
protein is indeed interacting with the peptide on the surface.
Addition of 3.3 lM MMP-8 to the peptide bound amine-
terminated surfaces resulted in a large increase in height
(20 Å) supporting the idea that the peptide binds MMP-8
(Fig. 3) and is not simply abstracting metal from the MMP-
8. A concentration dependent binding study was carried out
with a series of different MMP-8 concentrations (0.1–3.3 lM
from the same batch of protein with studies performed on
the same day). For the amine-terminated SAMs with similar
amounts of peptide grafted to the surface, a concentration
dependent response was observed (Fig. 4). As the MMP-8
concentration was increased, an increase in the average
thickness was observed. In this graph, the data have been
plotted to show the thickness increase due to protein incuba-
tion relative to the peptide film. This response appears to
level out at the higher concentrations, consistent with satura-
tion of available binding sites.
D. MMP-8 fusion construct binding to peptide inhibitor
Although the data presented above are consistent with a
direct and tight binding of MMP-8 to MAP, these studies
were performed with an impure sample containing some
fragments that may include the claMP Tag. Potential inter-
ferences due to interactions of the claMP Tag with the sur-
face bound tether-MAP are expected to be reduced because
the tag becomes occupied with nickel during purification of
the fusion protein. Nonetheless, catalytically active MMP-8
fusion that does not encode the claMP Tag was also tested
after performing more extensive purification (and removal of
fusion partner) to confirm that binding is neither due to con-
taminating fragments nor from degradation products. While
degradation products and fragments are still present, they
should be different in this second construct (MMP-8 fusion
construct). In these studies, with normalization of peptide
amount coupled to the surface, a very similar concentration
dependent binding was observed (Fig. 5).
FIG. 3. Ellipsometric thickness for adsorption of 3.3 lM claMP-link-MMP-8
fusion construct: (1) initial, (2) after peptide coupling, and (3) after MMP-8
incubation. Red hashed bars are R-OH samples, and blue solid bars are R-
NH2 samples. Error bars represent standard deviation of measurements of
replicate samples (n¼ 3).
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The MMP-8 fusion sample has increased purity compared
to the claMP-link-MMP-8 fusion construct, but it is less stable
and degrades more significantly with time. This prevents the
data from the two MMP-8 constructs from being compared
quantitatively. Additionally, the MMP-8 fusion construct
showed increased nonspecific adsorption at high concentra-
tions on the hydroxyl-terminated control samples relative to
the claMP-link-MMP-8 fusion construct. However, the fact
that the same trend in binding is observed with these two in-
dependent MMP-8 constructs provides strong evidence that
MMP-8 is interacting with the peptide and forming a long-
lived bound complex (on the time scale of these experiments)
at the surface and that this thickness increase is not the result
of nonspecific adsorption.
E. Removal of MMP-8 and Zn21 binding to tether-MAP
Figure 6 shows an experiment similar to that shown in
Fig. 3, at a different protein concentration (1.1 lM), but it
also shows the results of experiments subsequent to the
MMP-8 adsorption step. Repeated washing with denaturants
and acetate buffers resulted in the successful removal of the
protein as evidenced by the decrease in thickness. The
decreased thickness is equivalent to the value observed prior
to MMP-8 incubation as shown in step 4 of Fig. 6.
In order to ensure that the large increase in height observed
upon MMP-8 incubation was due to an interaction with
MMP-8 and not a result of a conformational change in the
surface bound tether-MAP peptide due to zinc ion binding,
we incubated the peptide modified SAMs in zinc ions
(10–100 lM ZnSO4 for 30–120 min). After incubation
in zinc ions, no significant change in height was observed
(Fig. 6). This demonstrates that binding of the Zn2þ ions to
the peptide would not provide a significant change in thick-
ness, and therefore suggests that the tether-MAP is not merely
abstracting the Zn2þ from the MMP-8 but rather interacting
directly with the MMP-8.
To specifically investigate the role of the metal binding
MAP Tag in the interaction between the surface bound pep-
tide and the MMP-8, the tether-MAP was incubated with ei-
ther zinc ions or nickel ions (10–100 lM ZnSO4 or NiSO4 for
30–120 min) to block the MAP Tag on the peptide. After
this blocking step, the thickness did not change significantly
upon addition of either metal (Fig. 6). In either case, zinc or
nickel ions, once the metal ions occupied sites on the surface
a greatly decreased amount of MMP-8 binding was observed
on the surface upon exposure to the MMP-8. In the case of
the MMP-8 fusion construct, for the highest concentration of
MMP-8 used (7.9 lM) without the metal blocking a thickness
of 15.5 6 0.9 Å was observed (Fig. 5). However, when the
FIG. 4. Concentration dependent binding for claMP-link-MMP-8 fusion con-
struct. Red open circles () are for the R-OH control samples and the blue
closed squares () are the R-NH2 samples.
FIG. 5. Concentration dependent binding for MMP-8 fusion construct. Red
open circles () are for the R-OH control samples, and the blue closed
squares () are the R-NH2 samples.
FIG. 6. Ellipsometric thickness for adsorption of 1.1 lM claMP-link-MMP-8 fusion construct (1) initial, (2) after peptide coupling, (3) after MMP-8 incubation,
(4) after protein removal with denaturant washes and acetate buffers, and (5) following Zn2þ incubation. Red hashed bars are R-OH samples and blue solid
bars are R-NH2 samples. Error bars represent standard deviation of measurements of replicate samples (n¼ 3).
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samples were preincubated in NiSO4, an increase of only
1.7 6 0.9 Å was observed for 7.9 lM MMP-8 solution. This
indicates that the metal binding site of the MAP Tag is play-
ing a critical role in the binding of the MMP-8, likely through
interaction with the Zn2þ in the active site of the MMP-8. A
very similar experiment was conducted on the claMP-link-
MMP-8 fusion construct with very similar results (not
shown), again indicating that the results are not due to some-
thing specific about this particular MMP-8 construct.
F. Role of tether-MAP density in MMP-8 binding
The binding of the protein to surfaces with different
amounts of peptide (created by using different amounts of
amine) was also investigated. Mixed SAM films with differ-
ent ratios of amine- and hydroxyl-termination were prepared
and peptide coupling experiments carried out. Generally, the
samples containing the most amine bound the most peptide
and those samples with the most peptide bound the most
MMP-8 as illustrated in Fig. 7. Interestingly, when MMP-8
binding studies were carried out on these surfaces with vary-
ing tether-MAP amounts, the 50% amine sample showed at
least as much MMP-8 binding as the 100% amine sample
even though the 100% amine sample showed the most pep-
tide adsorption. This may be a result of steric interactions
which block some of the peptide from being able to bind
MMP-8 and suggests that the optimum density of the peptide
for the binding experiments may be lower than that observed
for the 100% amine-terminated SAMs used in this
investigation.
IV. SUMMARY AND CONCLUSIONS
The mechanism of MMP-8 inhibition by the tether-MAP
peptide was investigated using ellipsometry and two different
MMP-8 constructs. After exposure of the peptide coupled
surfaces to MMP-8, an increase in thickness was observed,
suggesting a long-lived binding interaction between the two
species. The blocking of the metal binding site in the tether-
MAP peptide greatly reduced the binding interaction. These
results, plus the ability to extract MMP-8 from the surface
using acidic pH and chelators, strongly suggest that MMP-8
inhibition occurs through a mechanism involving the
interaction between the MAP Tag and the Zn2þ active site in
MMP-8. Understanding of the mechanism for MMP-8 inhibi-
tion by the tether-MAP peptide will contribute to the design
of more potent MMP inhibitors and/or assays for MMP levels
which are critically important in a variety of pathologic dis-
ease states.
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